Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.

Abstract

Aim: To describe clinical outcomes after complete surgical resection of stage IIB and IIC melanoma. Methods: Adult patients (n=567) with stage IIB or IIC cutaneous melanoma initially diagnosed and completely resected from 2008-2017 were identified using data from a US community-based oncology network. Results: Median patient follow-up was 38.8months from melanoma resection to death, last visitor data cutoff (31 December 2020). For stage IIB (n=375; 66%), Kaplan-Meier median real-world recurrence-free survival (rwRFS) was 58.6months (95% CI, 48.6-69.5). For stage IIC (n=192; 34%), median rwRFS was 29.9months (24.9-45.5). Overall, 44% of patients had melanoma recurrence or died; 30% developed distant metastases. Conclusion: Melanoma recurrence was common, highlighting the need for effective adjuvant therapy for stage IIB and IIC melanoma.